Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $25 price target Cantor tells investors in a research note that “this is about as high conviction a call as we’ll ever have” for a pre-commercial program. Trevi’s Haduvio, a mixed opioid agonist/antagonist in development for chronic cough, has shown a very consistent and very strong reduction in cough across multiple Phase 2 studies in interstitial pulmonary fibrosis and refractory chronic cough and is the first and only drug to show positive data in both IPF and RCC, the firm says.